Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Item

http://www.wikidata.org/entity/Q37334588

Q37334588

about

Insight to drug delivery aspects for colorectal cancer Whole Tumor Antigen Vaccines: Where Are We?Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies Developing strategies in the immunotherapy of leukemias Recent advance in antigen-specific immunotherapy for acute myeloid leukemia Evaluation of current cancer immunotherapy: hemato-oncology Targeting the innate immune system as immunotherapy for acute myeloid leukemia Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.Chemoimmunotherapy.Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model Prostate cancer as a model for tumour immunotherapy.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study Therapeutic cancer vaccines: current status and moving forward.DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies Multiple vaccinations: friend or foe.Lymphatic endothelial cells support tumor growth in breast cancer.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells Preimmunization of donor lymphocytes enhances antitumor immunity of autologous hematopoietic stem cell transplantation.Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.Immunotherapy prospects for acute myeloid leukaemia.Cellular vaccine approaches Vaccines as consolidation therapy for myeloid leukemia.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Vaccination strategies in lymphomas and leukaemias: recent progress.Current strategies in immunotherapy for acute myeloid leukemia.Ipilimumab in prostate cancer.Chemoimmunotherapy: reengineering tumor immunity.Cancer immunotherapies, their safety and toxicity.Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Immunotherapy in acute myeloid leukemia.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Vaccination strategies to improve outcome of hematopoietic stem cell transplant in leukemia patients: early evidence and future prospects.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.

P2860

Q26774682-F07F5443-75ED-4EA7-9919-80DC9250BB0C Q26783866-D1893632-737F-4D84-8765-14EF6F24E3CC Q26864603-97F569E6-FCE2-4BEB-8714-0F1A2E1BBE23 Q26996310-80B60414-1AD2-40D8-B0E2-6F404605A194 Q27005765-984840BF-E943-458A-927A-115CC7E8BE11 Q27006179-3FF45430-515D-42BE-87B8-16B0D86CEBB1 Q27015876-D70BBCED-3012-4E6B-B485-FB5A1A580F00 Q27021570-641B750E-F123-481D-A8EB-2F4F9E0E6746 Q30249246-EF1939F7-1CD2-40B7-A455-FA1B14F794CA Q34038443-5E913726-D247-4021-8054-77D6327F3BCE Q34058792-17DA7F43-BCCF-4CE7-9B0B-97F0C77FB465 Q34718187-4FE5F763-063F-47FA-A4A5-9301B5A7ACA6 Q34856875-F5DEE984-2B88-4422-8C8C-ABDC0729367C Q34980976-0F273501-A715-4188-B110-5724B7D8976F Q35886589-0057232B-BB8F-4397-A87D-B607722DE997 Q35894347-1E2EF9D8-80D8-43BD-938A-28022B0FF72B Q36544893-2D90ECB1-044B-4DDB-8837-FA7E4F2C2C97 Q36734688-69B6B1E8-D624-46F3-8D4F-CB685CACC2BD Q37057680-1DB8265F-71B9-40EA-BCC2-5E6CC55DB550 Q37123927-C7520123-32C9-4E7B-8520-107ACF2861D7 Q37482548-E73602A1-104C-4812-A08F-91D9DF1C9BF2 Q37574653-BBFBF1D8-D5C6-49BD-92EF-6F31A0656A71 Q37763280-B04989D4-5498-4C4A-8017-C5F83C9D46C7 Q37778690-091DBA69-55EA-4418-8FFE-9075301A2343 Q37842342-01994712-F79E-488F-837B-A1BDCB0A6309 Q37868974-0ACCA7B2-3B94-40B4-B6F6-2CDBF8E882ED Q37873932-0BC50D02-9B83-424D-92D1-0F5B78118D8C Q37929157-D365CD75-BD7F-444C-8DBF-8F7887E06579 Q38068967-2500D66B-9738-4F1B-B195-9C476C5C57C4 Q38069640-E573DB8F-6DB5-4394-A907-7B7D5BF247DB Q38079749-7149D78A-AECA-41E2-8F03-1295A566CB1B Q38106230-E7659E72-1B16-4312-9337-52B63C50A928 Q38125532-26DABDFF-6CBC-487C-AF87-A914CB17060C Q38149916-90304848-3A84-4B82-A880-0FD6087ED7F4 Q38171574-D478748D-3C0C-4356-9431-98B0F11E96FE Q38195065-310039B5-DC52-4DE2-B52D-5FEBDE9C9EC0 Q38245948-21B48E94-2F40-42EF-9EFB-2228FBD495B8 Q38250205-17DEC043-61A0-46FA-A431-F0DBB4CACD94 Q38353123-885D8C33-AAB4-47D7-B536-487B1F6B4E77 Q38862302-4383F612-FD65-4F61-AC8B-4277A897C49D

P2860

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Item

http://www.wikidata.org/entity/Q37334588

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Granulocyte-macrophage colony- ...... acute myeloid leukemia (AML).

@en

type

Item

label

Granulocyte-macrophage colony- ...... acute myeloid leukemia (AML).

@en

prefLabel

Granulocyte-macrophage colony- ...... acute myeloid leukemia (AML).

@en

P1476

Granulocyte-macrophage colony- ...... acute myeloid leukemia (AML).

@en

P2093

Charles A Linker

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Daniel J Maslyar

http://www.w3.org/2001/XMLSchema#string

Dorie Sher

http://www.w3.org/2001/XMLSchema#string

Edwin P Alyea

http://www.w3.org/2001/XMLSchema#string

Hyam I Levitsky

http://www.w3.org/2001/XMLSchema#string

Ivan M Borrello

http://www.w3.org/2001/XMLSchema#string

Kristen M Hege

http://www.w3.org/2001/XMLSchema#string

Lloyd E Damon

http://www.w3.org/2001/XMLSchema#string

Lu Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

P304

1736-1745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-02-205278

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26320705

http://www.w3.org/2001/XMLSchema#string

P698

19556425

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

macrophage

leukemia

P932

2738565

http://www.w3.org/2001/XMLSchema#string

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

about

P2860

P2860

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932